Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Inclusion Criteria:

   - Minimum life expectancy of 12 weeks

   - The presence of a solid, malignant tumour that is resistance to standard therapies or
   for which no standard therapies exist

   - In the expansion for the study patients must have a tumour at least 1cm in size that
   can be measure using a CT or MRI scan, and provide a tumour sample to the sponsor
   company for testing of FGFR1 and/or 2 amplification

   - Expansion, 5 groups of advanced cancer

   - Solid tumours,FGFR1 and/or FGFR2 gene amplified

   - Squamous NSCLC, FGFR1 gene low & high amplified

   - Gastric adenocarcinoma, including the lower oesophagus/gastro-oesophageal junction,
   FGFR2 gene low & high amplified

   - Aged at least 25 years

Exclusion Criteria:

   - Treatment with any other chemotherapy, immunotherapy or anticancer agents within 3
   weeks before the first dose of study

   - An inability to be able to take the study medication

   - A bad reaction to AZD4547 or any drugs similar to it in structure or class.